Armistice Capital, LLC Travere Therapeutics, Inc. Call Options Transaction History
Armistice Capital, LLC
- $5.71 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TVTX
# of Institutions
230Shares Held
102MCall Options Held
1.71MPut Options Held
401K-
Janus Henderson Group PLC London, X09.54MShares$166 Million0.07% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$133 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$104 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C35.1MShares$88.7 Million0.1% of portfolio
-
State Street Corp Boston, MA3.48MShares$60.6 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.12B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...